B. Kelly

发表

Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.

L. Kaminskas, B. Kelly, Victoria M Mcleod, 2009, Molecular pharmaceutics.

A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems.

Ben J Boyd, Christopher J H Porter, Lisa M Kaminskas, 2012, Nanomedicine : nanotechnology, biology, and medicine.

Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy.

D. Owen, L. Kaminskas, B. Kelly, 2014, Journal of controlled release : official journal of the Controlled Release Society.

PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats.

L. Kaminskas, B. Kelly, Victoria M Mcleod, 2009, Journal of controlled release : official journal of the Controlled Release Society.

Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats.

D. Owen, D. Ascher, T. Velkov, 2015, Molecular pharmaceutics.

Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection site.

D. Owen, L. Kaminskas, B. Kelly, 2017, Nanomedicine : nanotechnology, biology, and medicine.

Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent.

D. Owen, L. Kaminskas, B. Kelly, 2013, Molecular pharmaceutics.

Reducing Dendrimer Generation and PEG Chain Length Increases Drug Release and Promotes Anticancer Activity of PEGylated Polylysine Dendrimers Conjugated with Doxorubicin via a Cathepsin-Cleavable Peptide Linker.

D. Owen, L. Kaminskas, B. Kelly, 2018, Molecular pharmaceutics.

Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

E. Hennessy, S. Fawell, B. Davies, 2021, Communications biology.

Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers.

D. Owen, L. Kaminskas, B. Kelly, 2011, Molecular pharmaceutics.

Surgical innovation revisited: A historical narrative of the minimally invasive “Agarwal sliding‐clip renorrhaphy” technique for partial nephrectomy and its application to an Australian cohort

D. Agarwal, A. Costello, N. Corcoran, 2021, BJUI compass.

Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker.

D. Owen, B. Kelly, Victoria M Mcleod, 2011, Journal of controlled release : official journal of the Controlled Release Society.

The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers.

B. Kelly, B. Boyd, G. Krippner, 2008, Molecular pharmaceutics.

Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models.

Ben J. Boyd, Christopher J. H. Porter, Carleen Cullinane, 2012, Molecular pharmaceutics.

Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

E. Hennessy, S. Fawell, B. Davies, 2021, Communications Biology.

Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy.

D. Owen, B. Kelly, Victoria M Mcleod, 2014, Journal of controlled release : official journal of the Controlled Release Society.

Doxorubicin Conjugation and Drug Linker Chemistry Alter the Intravenous and Pulmonary Pharmacokinetics of a PEGylated Generation 4 Polylysine Dendrimer in Rats.

D. Owen, B. Kelly, Victoria M Mcleod, 2018, Journal of pharmaceutical sciences.

Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats.

D. Owen, D. Ascher, T. Velkov, 2015, Molecular pharmaceutics.

Abstract 1716: Anticancer activity of the taxane nanoparticles, DEP®docetaxel and DEP®cabazitaxel

D. Owen, B. Kelly, Victoria M Mcleod, 2020, Clinical Research (Excluding Clinical Trials).